Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study

[1]  M. Arias Gómez,et al.  Associated Inosine to interferon: results of a clinical trial in multiple sclerosis , 2015, Acta neurologica Scandinavica.

[2]  V. Morra,et al.  Uric acid: a potential biomarker of multiple sclerosis and of its disability , 2015, Clinical chemistry and laboratory medicine.

[3]  F. Jacques.  Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.

[4]  M. T. Pellecchia,et al.  Presence and progression of non‐motor symptoms in relation to uric acid in de novo Parkinson's disease , 2015, European journal of neurology.

[5]  G. Nagels,et al.  The Symbol Digit Modalities Test as sentinel test for cognitive impairment in multiple sclerosis , 2014, European journal of neurology.

[6]  M. T. Pellecchia,et al.  Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? , 2014, Parkinsonism & related disorders.

[7]  F. Ashtari,et al.  Serum uric acid level in patients with relapsing-remitting multiple sclerosis , 2013, Journal of Clinical Neuroscience.

[8]  M. Trojano,et al.  Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients , 2012, PloS one.

[9]  Kaiwen Xiao,et al.  Serum uric acid levels in patients with multiple sclerosis: a meta-analysis , 2012, Neurological research.

[10]  Á. Guerrero,et al.  Serum uric acid levels in multiple sclerosis patients inversely correlate with disability , 2011, Neurological Sciences.

[11]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[12]  C. Polman,et al.  Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. , 2009, Clinical biochemistry.

[13]  C. Lederer,et al.  Disability as an outcome in MS clinical trials , 2008, Neurology.

[14]  A. Hofman,et al.  Serum uric acid and cognitive function and dementia. , 2008, Brain : a journal of neurology.

[15]  Bin Zhang,et al.  Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. , 2008, Multiple sclerosis.

[16]  H. D. Vries,et al.  Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology , 2007, Brain Research Reviews.

[17]  S. Sorbi,et al.  The Rao’s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population , 2006, Multiple sclerosis.

[18]  P. Pasqualetti,et al.  The Symbol Digit Modalities Test - Oral version: Italian normative data. , 2006, Functional neurology.

[19]  C. Knapp,et al.  Serum uric acid levels in optic neuritis , 2004, Multiple sclerosis.

[20]  H. Koprowski,et al.  Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Rosati,et al.  Serum uric acid and multiple sclerosis , 2002, Neurological Sciences.

[22]  B. Miličić,et al.  Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood–brain barrier dysfunction , 2002, European journal of neurology.

[23]  B. Miličić,et al.  High-dose Methylprednisolone Therapy in Multiple Sclerosis Increases Serum Uric Acid Levels , 2002, Clinical chemistry and laboratory medicine.

[24]  H. Koprowski,et al.  Uric acid levels in patients with multiple sclerosis: analysis in mono- and dizygotic twins , 2001, Multiple sclerosis.

[25]  J. Marinković,et al.  Uric acid levels in sera from patients with multiple sclerosis , 2001, Journal of Neurology.

[26]  L. Kappos,et al.  Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis , 2000, Multiple sclerosis.

[27]  W. Pryor,et al.  Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. , 2000, Archives of biochemistry and biophysics.

[28]  H. Koprowski,et al.  Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood–CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  P. Klivényi,et al.  Nonenzymatic antioxidants of blood in multiple sclerosis , 1999, Journal of Neurology.

[30]  H. Koprowski,et al.  Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  O. Bagasra,et al.  Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[33]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[34]  Muna Shakeeb Tawfiq.  Rating Neurological Impairment in Multiple Sclerosis , 2016 .

[35]  I. Majsterek,et al.  Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. , 2012, Clinical biochemistry.

[36]  J. Kaye,et al.  Uric acid as a CNS antioxidant. , 2010, Journal of Alzheimer's disease : JAD.

[37]  T. Pekmezović,et al.  Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis , 2009, Clinical chemistry and laboratory medicine.

[38]  J. Hetta,et al.  Hypoxanthine, xanthine, urate and creatinine concentration gradients in cerebrospinal fluid. , 1988, Upsala journal of medical sciences.